Amgen posts results for completed Phase 4 romosozumab and Phase 1 rocatinlimab trials

Amgen's update this week centers on two completed trials reporting results, alongside no change to a collaborator-sponsored observational study.

• A Phase 4 trial of romosozumab, marketed as "EVENITY®," tested the drug in postmenopausal women in India with osteoporosis at high risk of fracture. The study is now marked completed, with results first posted on 2026-10-21 and last update posted the same day.¹ The trial enrolled 100 participants in a single-group design, with participants dosed with two subcutaneous injections of romosozumab once a month for 12 months.¹ Posted safety results show 73 participants experienced treatment-emergent adverse events and 6 experienced treatment-emergent serious adverse events among those receiving romosozumab 210 mg SC once monthly.¹
• A Phase 1 open-label trial compared the pharmacokinetics of rocatinlimab (AMG 451) given by subcutaneous injection from a vial versus a prefilled syringe. The study population consisted of healthy male or female participants between 18 and 65 years of age, with atopic dermatitis listed only as a condition keyword rather than a study requirement.² The trial is marked completed, with results first posted on 2026-10-23.² Enrollment reached 240 participants.²
• "EMPOWER" (NCT07883564), an observational implementation-science study testing whether workflow strategies improve guideline-recommended LDL-C management in high-risk cardiovascular patients, remains not yet recruiting with an estimated start of October 2026.³ The study is sponsored by Cardiology Consultants of Philadelphia, with Amgen and Thomas Jefferson University listed as collaborators.³